United States Patent 8,318,817: Scope, Claim Boundaries, and Patent Landscape for Intra-Tympanic Sustained Release Antimicrobials
United States Patent 8,318,817 covers a method of treating otic infection or inflammation via single-administration intratympanic delivery of a liquid-at-room-temperature, sustained-release multiparticulate antimicrobial formulation that uses a polyoxyethylene-polyoxypropylene copolymer (poloxamer class) defined by non-gelation viscosity, gelation viscosity, gelation temperature, and osmolarity < 1000 mOsm/L. The enforceable claim core is the intersection of: (1) intratympanic delivery at or about room temperature, (2) specific poloxamer viscosity/temperature/osmolarity constraints, and (3) multiparticulate antimicrobial sustained release for ≥5 days (and ≥10 days in dependent scope).
What is the claim scope in 8,318,817 (independent claim 1)?
Claim 1: Structural and functional limits that define infringement
Claim 1 is a treatment method claim with both formulation and performance limitations. Each element constrains the practicing product and dosing method:
A. Indication / route
- Treating an otic infection or inflammation
- Intra-tympanic administration to “an individual in need thereof”
B. Therapeutic agent
- A multiparticulate antimicrobial agent
- “Therapeutically effective amount” is required (standard efficacy term)
C. Formulation components and constraints
The composition further comprises:
1) a-copolymer of polyoxyethylene and polyoxypropylene
- “in an amount sufficient” to provide:
- Non-gelation viscosity that “allows injection with a 18–31 gauge needle through the tympanic membrane into the ear”
- Gelation viscosity between about 15,000 cP and about 1,000,000 cP
- Gelation temperature between about room temperature and about body temperature
2) Osmolarity constraint
D. Physical state and dosing temperature
- The composition is a liquid at about room temperature
- Administered at or about room temperature
E. Sustained-release performance
- Provides sustained release of the antimicrobial agent in the ear for at least 5 days after a single intratympanic administration
Key takeaways from claim 1 boundaries
- The formulation must be injectable at room temperature through 18–31G needles (viscosity must be low enough to permit injection).
- The same formulation must gel on heating (gelation temperature spans room temperature to body temperature; gelation viscosity must fall within 15,000 to 1,000,000 cP).
- The formulation must have osmolarity under 1000 mOsm/L, limiting salts/osmolytes and total ionic content.
- The sustained-release window is anchored to ≥5 days after a single dose.
Which dependent claims narrow the scope (claims 2–11)?
Claim 2: Duration hard cap
- Sustained release for at least 10 days (narrower temporal performance)
Claims 3–6: Antimicrobial identity
- Claim 3: antimicrobial is an antibiotic
- Claim 4: antibiotic is a quinolone antibiotic
- Claim 5: quinolone antibiotic is selected from a listed set:
- ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nonfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin
- Claim 6: quinolone antibiotic is ciprofloxacin (narrowest identity among the quinolones)
Claims 7–9: Polymer specificity
- Claim 7: copolymer is poloxamer 407
Claims 8–9: Disease subtype
- Claim 8: otic infection or inflammation is otitis media
- Claim 9: otitis media is otitis media with effusion
Claims 10–11: Clinical context
- Claim 10: otic infection or inflammation is associated with an otic intervention
- Claim 11: intervention is surgery for insertion of a tympanostomy tube, where the condition is otitis media with effusion associated with tympanostomy tube insertion
Where are the practical infringement pressure points?
1) The poloxamer viscosity and gelation window is the main technical gate
Claim 1 requires:
- Non-gelation viscosity enabling injection via 18–31 gauge
- Gelation viscosity 15,000 cP to 1,000,000 cP
- Gelation temperature between room temperature and body temperature
This creates two infringement pressure areas:
- A competitor must hit both the injection and gelation performance profiles.
- Many poloxamer systems can gel, but the claim binds the system to an injection-compatible viscosity at room temperature and a gelation viscosity in the specified band.
2) The osmolarity limit (<1000 mOsm/L) restricts formulation space
For otic delivery, osmolarity is often treated as a tolerability variable. Here it is explicitly claim-limiting. Any alternative vehicle must stay below 1000 mOsm/L.
3) “Multiparticulate” is an additional enforceability lever
The antimicrobial agent must be multiparticulate. That term can be pivotal in product design:
- If a competitor uses a purely dissolved antibiotic (single-phase molecular solution) rather than multiparticulate particulate systems, they may fall outside claim 1.
- If they use microparticles, aggregates, or beads, they may remain inside.
4) The sustained-release metric is tied to a dosing regimen
The claim requires sustained release for at least 5 days after a single intratympanic administration. A competitor dosing more frequently or producing shorter residence time is a non-infringement route if the claim term is not met.
What is the claim structure that matters for validity and design-around?
Independent method claim with formulation-defined limitations
Because claim 1 is a method of treatment, the patentee’s infringement theory typically depends on proving:
- the clinician’s intratympanic administration at or about room temperature
- of a formulation meeting the copolymer viscosity/gelation and osmolarity limitations
- containing a multiparticulate antimicrobial
- and achieving ≥5 days sustained release after a single dose
This means design-around targets include:
- altering formulation to change injection/gelation profile outside the ranges
- raising osmolarity above 1000 mOsm/L (while risking tolerability)
- changing from multiparticulate to non-multiparticulate antimicrobial form
- changing sustained release profile below 5 days post-single administration
- shifting administration temperature or dosing schedule (though “at or about room temperature” is broad)
Dependent claims create fallback positions
Dependent claims 2, 3–7, and 8–11 allow claim coverage to fall back when:
- The competitor matches claim 1 but uses only certain antibiotics (quinolones and especially ciprofloxacin)
- The competitor uses a specific polymer identity (poloxamer 407)
- The clinical population is narrower (otitis media with effusion, tympanostomy tube-associated effusion)
How does the claim language map to a likely product concept?
The claim reads like a typical thermoresponsive poloxamer hydrogel system used with particulate antibiotics:
- At room temperature: low viscosity liquid for injection through small-bore needles.
- As it warms: viscosity increases to a gel state with defined cP range.
- It releases antibiotic over time in the middle ear for multiple days.
The combination of:
- room-temperature injectability
- gelation viscosity band
- osmolarity cap
- sustained release time
is the core technical recipe covered by the claim.
What is the likely patent landscape around this claim scope (US-focused)?
1) Adjacent concept space likely includes intratympanic antibiotic delivery systems
Within the otic space, there are recurring themes across patents:
- intratympanic delivery methods
- thermoresponsive gels (including poloxamer derivatives)
- sustained release antibiotic formulations
- treating otitis media and otitis media with effusion
Where 8,318,817 tends to sit in that landscape:
- It is not a generic intratympanic antibiotic method.
- It specifically claims a thermoresponsive copolymer system with injection and gelation viscosity/temperature requirements and osmolarity < 1000 mOsm/L, plus multiparticulate delivery and a quantified sustained-release timeframe.
2) Potential overlap hotspots
Based on the claim’s structure, most competitive overlap is expected where a patent also:
- uses a poloxamer-like copolymer for thermoresponsive gelation
- maintains osmolarity within a biocompatible band
- delivers antibiotics intratympanically as a sustained release after a single administration
3) Main design-around regions
A competitor attempting to avoid 8,318,817 would likely pursue one or more of:
- Non-poloxamer thermoresponsive systems (different polymer chemistry or not meeting the “a-copolymer of polyoxyethylene and polyoxypropylene” requirement)
- Poloxamer systems tuned outside gelation viscosity band (below 15,000 cP or above 1,000,000 cP)
- Osmolarity above 1000 mOsm/L (if tolerability and regulatory acceptability allow)
- Alternative antibiotic forms that are not “multiparticulate”
- Release profiles below the ≥5 day requirement after a single dose
- Administration conditions outside “at or about room temperature” (though practical ranges are likely to be argued)
Claim-by-claim risk grid for competitive freedom-to-operate (conceptual mapping)
| Element of Claim 1 |
What a competitor must match to infringe |
Typical design-out options |
| Intratympanic treatment of otic infection/inflammation |
Use intratympanic route for relevant diagnosis |
Different route or indication framing |
| Multiparticulate antimicrobial |
Use particulate/multiparticulate antibiotic system |
Use dissolved or non-multiparticulate form |
| Polyoxyethylene-polyoxypropylene copolymer |
Use α-copolymer of EO/PO |
Use different polymer class |
| Injection through 18–31G via non-gelation viscosity |
Injection-ready liquid at RT through small needle |
Tune viscosity too high for injection or too low to meet gelation behavior |
| Gelation viscosity 15,000–1,000,000 cP |
Thermogel viscosity within band |
Shift outside band |
| Gelation temp room–body |
Thermoresponsive gelation in that temperature window |
Shift gelation outside window |
| Osmolarity < 1000 mOsm/L |
Formulation must have osmolarity below cap |
Raise osmolarity (with tolerability/regulatory risk) |
| Single dose provides ≥5 days sustained release |
Performance must meet release time |
Release faster; require multiple dosing |
Operational implications for R&D and investment
Product development and lab testing must be aligned to claim parameters
For R&D teams, the claim creates a direct experimental checklist:
- needle injectability through 18–31 gauge
- measured cP viscosity states at room temperature vs body-temperature gelation
- confirmed osmolarity
- release characterization in a way that supports “sustained release for at least 5 days after a single administration”
For investment teams, the main diligence focus is whether a candidate platform:
- uses the same polymer family and comparable viscosity/gelation parameters
- uses multiparticulate antibiotic presentation
- supports single-dose sustained release meeting the ≥5 day bar
Key Takeaways
- 8,318,817 is anchored on a thermoresponsive polyoxyethylene-polyoxypropylene copolymer formulation that is injectable at room temperature and becomes a gel with 15,000 to 1,000,000 cP gelation viscosity between room and body temperature, plus osmolarity < 1000 mOsm/L.
- The method requires multiparticulate antibiotics administered intratympanically at/near room temperature with sustained release for at least 5 days after a single dose.
- Dependent claims narrow to ≥10 days, quinolone antibiotics, specific quinolones including ciprofloxacin, and poloxamer 407, plus narrower clinical subtypes like otitis media with effusion and post tympanostomy tube insertion context.
- For design-around, the most leverage comes from violating any one of: copolymer chemistry, viscosity/gelation parameters, osmolarity threshold, multiparticulate requirement, or ≥5 day sustained release after single administration.
FAQs
1) Is the claim limited to ciprofloxacin?
No. Ciprofloxacin is covered in dependent claim 6, but claim 1 covers any multiparticulate antimicrobial, and claims 3–5 narrow further to quinolone antibiotics with a listed set that includes ciprofloxacin.
2) Does the patent require poloxamer 407 specifically?
No. Poloxamer 407 is specified in dependent claim 7. Claim 1 covers the broader class of α-copolymers of polyoxyethylene and polyoxypropylene that meet the injection and gelation viscosity/temperature constraints.
3) How long must the sustained release last for independent claim 1?
At least 5 days after a single intratympanic administration.
4) What is the osmolarity limitation?
The composition must have osmolarity of less than 1000 mOsm/L.
5) What needle size range is explicitly called out?
The formulation must allow injection with an 18 to 31 gauge needle through the tympanic membrane.
References
[1] United States Patent 8,318,817. Claims provided in the prompt.
